Trace Neuroscience, Inc. is a biotechnology company developing genetic medicines for neurodegenerative diseases. Its lead investigational medicine, TRCN-1023, is designed to restore the function of the UNC13A protein, which is disrupted in most people living with amyotrophic lateral sclerosis (ALS). - View it on GitHub